Find a Supplier
REQUEST A DEMO
Archive
Contact Us Subscribe to Newsletter

Archive | HAPILA GmbH

Page 3 of 3
HAPILA showcases advanced API development expertise at CPhI Worldwide Frankfurt
HAPILA showcases advanced API development expertise at CPhI Worldwide Frankfurt

Wednesday 23rd October 2019

By  HAPILA GmbH Learn More >
HAPILA gains ISO certification and FDA approval
HAPILA gains ISO certification and FDA approval

Friday 4th October 2019

By  HAPILA GmbH Learn More >
HAPILA Substance Purification
HAPILA Substance Purification

Monday 26th August 2019

By  HAPILA GmbH Learn More >
HAPILA anti-TB agent BTZ043 wins Germany’s IQ Innovation Award
HAPILA anti-TB agent BTZ043 wins Germany’s IQ Innovation Award

Friday 9th August 2019

By  HAPILA GmbH Learn More >
Anti-TB substance BTZ-043 passes Clinical Trial Phase Ia milestone
Anti-TB substance BTZ-043 passes Clinical Trial Phase Ia milestone

Wednesday 17th July 2019

By  HAPILA GmbH Learn More >
HAPILA showing advanced drug CDMO services at Chemspec Europe
HAPILA showing advanced drug CDMO services at Chemspec Europe

Wednesday 12th June 2019

By  HAPILA GmbH Learn More >
HAPILA gains cGMP status for leading edge anti-tuberculosis API manufacture
HAPILA gains cGMP status for leading edge anti-tuberculosis API manufacture

Tuesday 7th May 2019

By  HAPILA GmbH Learn More >
HAPILA Chemical Synthesis
HAPILA Chemical Synthesis

Thursday 21st March 2019

By  HAPILA GmbH Learn More >
Page 3 of 3